Back
 Health  Vol.10 No.5 , May 2018
Evaluation of Blood Pressure Control Medicines Using Health and Medical Checkup Data in Japan: Alternative Methods for Randomized Controlled Trials
Abstract: Background: Many people take medicines to control high blood pressure (BP), or hypertension. Randomized clinical trials (RCT) are usually used for the evaluation of effects of medicines. However, RCT have some serious problems. Data and Methods: We evaluated the effects of BP medicines in Japan using a dataset containing 113,979 cases. We employed four statistical methods in the analysis. First, we simply compared the systolic blood pressure (SBP) of individuals with and without BP medicines. We then used a regression model with a dummy variable, representing taking medicines or not. We replaced the dummy variable by its expected value, and estimated the regression model again. Finally, we selected individuals who had both taken and not taken medicines at different times. The effect of sample selection was also considered in the estimation. Results: For the simple comparison, SBP with BP medicines was 11 mmHg higher than without medicines. In the next regression analysis, SBP with BP medicines was still 5 mmHg higher. When the dummy variable was replaced by its expected value, SBP with medicines decreased by 7 mmHg. For individuals taking medicines at some times and not at others, SBP decreased by 9 and 8 mmHg in models with and without a sample bias correction, respectively. Conclusion: The methods eliminated some problems of RCT and might be attractive. However, we obtained contradictory conclusions depending on the statistical methods employed, despite using the identical dataset. Statistical methods must be selected carefully to obtain a reliable evaluation. Limitations: The dataset was observatory, and the sample period was only 3 years.
Cite this paper: Nawata, K. , Sekizawa, Y. and Kimura, M. (2018) Evaluation of Blood Pressure Control Medicines Using Health and Medical Checkup Data in Japan: Alternative Methods for Randomized Controlled Trials. Health, 10, 587-603. doi: 10.4236/health.2018.105047.
References

[1]   World Health Organization (2018) Raised Blood Pressure.
http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/

[2]   Ministry of Health, Welfare, and Labor (2017) Heisei 27 Nendokokuminiryouhi No Gayou (Summary of National Medical Expenditures, Fiscal Year 2015). (In Japanese)

[3]   Nawata, K. and Kimura, M. (2017) An Analysis of the Medical Costs of and Factors Affecting Diabetes Using the Medical Checkup and Payment Dataset in Japan: Can We Reduce the Prevalence of Diabetes? Health, 9, 1113-1127.
https://doi.org/10.4236/health.2017.98081

[4]   Nawata, K. and Kimura, M. (2017) Evaluation of Medical Costs of Kidney Diseases and Risk Factors in Japan. Health, 9, 1734-1749.
https://doi.org/10.4236/health.2017.913127

[5]   Codliffe, S. and Link, C.R. (2014) Racial Differences in the Effects of Hypertension and Obesity on Health Expenditures by Diabetes in the US. Applied Economics Letters, 21, 280-283.
https://doi.org/10.1080/13504851.2013.856990

[6]   Mojon-Azzi, S. and Sousa-Pazo, A. (2011) Hypertension and Life Satisfaction: An Analysis Using Data from the Survey of Health, Aging and Retirement in Europe. Applied Economics Letters, 18, 183-187.
https://doi.org/10.1080/13504850903508291

[7]   Joffres, M.R., Mamet, P., MacLean, D.R., et al. (2001) Distribution of Blood Pressure and Hypertension in Canada and the United States. American Journal of Hypertension, 14, 1099-1105.
https://doi.org/10.1016/S0895-7061(01)02211-7

[8]   Hansson, L.A., Zanchetti, A., Carruthers, S.G., et al. (1998) Effects of Intensive Blood-Pressure Lowering and Low-Dose Aspirin in Patients with Hypertension: Principal Results of the Hypertension Optimal Treatment (HOT) Randomised Trial. Lancet, 351, 1755-1762.
https://doi.org/10.1016/S0140-6736(98)04311-6

[9]   Greenhalgh, T. (2014) How to Read a Paper: The Basics of Evidence-Based Medicine. 5th Edition, Wiley Blackwell, Hoboken.

[10]   Dickersin, K., Chan, S.S., Chalmersx, T.C., et al. (1987) Publication Bias and Clinical Trials. Controlled Clinical Trials, 8, 343-353.
https://doi.org/10.1016/0197-2456(87)90155-3

[11]   Hopewell, S., Loudon, K., Clarke, M.J., et al. (2009) Publication Bias in Clinical Trials Due to Statistical Significance or Direction of Trial Results (Review). John Wiley & Sons, Hoboken.
http://sverigesradio.se/diverse/appdata/isidor/files/83/5775.pdf

[12]   Turner, E.H., Matthews, A.M., Linardatos, E., et al. (2008) Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy. New England Journal of Medicine, 358, 252-260.
https://doi.org/10.1056/NEJMsa065779

[13]   Lexchin, J., Bero, L.A., Djulbegovic, B. and Clark, O. (2003) Pharmaceutical Industry Sponsorship and Research Outcome and Quality: Systematic Review. BMJ, 326, 1167.
https://doi.org/10.1136/bmj.326.7400.1167

[14]   Perlis, R.H., Perlis, C.S., Wu, Y., et al. (2005) Industry Sponsorship and Financial Conflict of Interest in the Reporting of Clinical Trials in Psychiatry. American Journal of Psychiatry, 162, 1957-1960.
https://doi.org/10.1176/appi.ajp.162.10.1957

[15]   Lundh, A., Lexchin, J., Mintzes, B., et al. (2017) Industry Sponsorship and Research Outcome. Cochrane Database of Systematic Reviews.
http://cochranelibrary-wiley.com/doi/10.1002/14651858.MR000033.pub3/full
https://doi.org/10.1002/14651858.MR000033.pub3


[16]   Kyoto Prefectural University of Medicine (2013) Research Report about the Kyoto Heart Study Clinical Study. (In Japanese)

[17]   Ikei University School of Medicine (2013) About Retraction of Jikei Heart Study Paper. (In Japanese)

[18]   Japanese Society of Hypertension (2013) Report of the Independent Committee for Clinical Trials. (In Japanese)

[19]   Novartis Pharma (2018) For Restoring Credibility. (In Japanese)
https://www.novartis.co.jp/about-us/credibility

[20]   Pak, T.R., Rodriguez, M.D. and Roth, F.P. (2015) Why Clinical Trials Are Terminated.
https://www.biorxiv.org/content/biorxiv/early/2015/07/02/021543.full.pdf

[21]   Staessen, J.A., Fagard, R., Thijs, L., et al. (1997) Randomised Double-Blind Comparison of Placebo and Active Treatment for Older Patients with Isolated Systolic Hypertension. The Lancet, 350, 757-764.
https://doi.org/10.1016/S0140-6736(97)05381-6

[22]   Forette, F., Seux, M.L., Staessen, J.A., et al. (1998) Prevention of Dementia in Randomised Double-Blind Placebo-Controlled Systolic Hypertension in Europe (Syst-Eur) Trial. The Lancet, 352, 1347-1351.
https://doi.org/10.1016/S0140-6736(98)03086-4

[23]   Brown, M.J., Palmer, C.R., Castaigne, A., et al. (2000) Morbidity and Mortality in Patients Randomised to Double-Blind Treatment with a Long-Acting Calcium-Channel Blocker or Diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). The Lancet, 356, 366-372.
https://doi.org/10.1016/S0140-6736(00)02527-7

[24]   Simonneau, G., Barst, R.J., Galie, N., et al. (2002) Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension: A Double-Blind, Randomized, Placebo-Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 165, 800-804.
https://doi.org/10.1164/ajrccm.165.6.2106079

[25]   Lithell, H., Hansson, L., Ingmarb, S., et al. (2003) The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal Results of a Randomized Double-Blind Intervention Trial. Journal of Hypertension, 21, 875-886.
https://doi.org/10.1097/00004872-200305000-00011

[26]   Julius, S., Kjeldsen, S.E., Weber, M., et al. (2004) Outcomes in Hypertensive Patients at High Cardiovascular Risk Treated with Regimens Based on Valsartan or Amlodipine: The VALUE Randomised Trial. The Lancet, 363, 2022-2031.
https://doi.org/10.1016/S0140-6736(04)16451-9

[27]   Philipp, T., Smith, T.R., Glazer, R., et al. (2007) Two Multicenter, 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Studies Evaluating the Efficacy and Tolerability of Amlodipine and Valsartan in Combination and as Monotherapy in Adult Patients with Mild to Moderate Essential Hypertension. Clinical Therapeutics, 29, 563-580.
https://doi.org/10.1016/j.clinthera.2007.03.018

[28]   Oparil, S., Yarows, S.A., Patel, S., et al. (2007) Efficacy and Safety of Combined Use of Aliskiren And Valsartan in Patients with Hypertension: A Randomised, Double-Blind Trial. The Lancet, 370, 221-229.
https://doi.org/10.1016/S0140-6736(07)61124-6

[29]   Warwickm J., Falaschetti, E., Rockwood, K., et al. (2015) No Evidence That Frailty Modifies the Positive Impact of Antihypertensive Treatment in Very Elderly People: An Investigation of the Impact of Frailty upon Treatment Effect in the Hypertension in the Very Elderly Trial (HYVET) Study, a Double-Blind, Placebo-Controlled Study of Antihypertensives in People with Hypertension Aged 80 and over. BMC Medicine, 13, 78.
https://doi.org/10.1186/s12916-015-0328-1

[30]   Dower, J.I., Geleijnse, J.M., Gijsbers, L., et al. (2015) Supplementation of the Pure Flavonoids Epicatechin and Quercetin Affects Some Biomarkers of Endothelial Dysfunction and Inflammation in (Pre)Hypertensive Adults: A Randomized Double-Blind, Placebo-Controlled, Crossover Trial. Journal of Nutrition, 145, 1459-1463.
https://doi.org/10.3945/jn.115.211888

[31]   Weber, M.A., Mansfield, T.A. and Cain, V.A. (2016) Blood Pressure and Glycaemic Effects of Dapagliflozin versus Placebo in Patients with Type 2 Diabetes on Combination Antihypertensive Therapy: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. The Lancet Diabetes & Endocrinology, 4, 211-220.
https://doi.org/10.1016/S2213-8587(15)00417-9

[32]   Brüll, B., Burak, C., Stoffel-Wagner, B., et al. (2017) Acute Intake of Quercetin from Onion Skin Extract Does Not Influence Postprandial Blood Pressure and Endothelial Function in Overweight-to-Obese Adults with Hypertension: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. European Journal of Nutrition, 56, 1347-1357.
https://doi.org/10.1007/s00394-016-1185-1

[33]   Juliene, G., Costa, J.G., Giolo, J.S., Mariano, I.M., et al. (2017) Combined Exercise Training Reduces Climacteric Symptoms without the Additive Effects of Isoflavone Supplementation: A Clinical, Controlled, Randomised, Double-Blind Study. Nutrition and Health, 23, 271-279.
https://doi.org/10.1177/0260106017727359

[34]   Behr, J., Nathan, S.D., Harari, S., et al. (2018) Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Risk of Pulmonary Hypertension: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study-Rationale and Study Design. Respiratory Medicine.

[35]   Rothman, K.J. and Michaels, K.B. (1994) The Continuing Unethical Use of Placebo Controls. New England Journal of Medicine, 331, 394-398.
https://doi.org/10.1056/NEJM199408113310611

[36]   Clark, P.I. and Leaverton, P.E. (1994) Scientific and Ethical Issues in the Use of Placebo Controls in Clinical Trials. Annual Review of Public Health, 15, 19-38.
https://doi.org/10.1146/annurev.pu.15.050194.000315

[37]   Temple, R. and Ellenberg, S.S. (2000) Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments: Part 1: Ethical and Scientific Issues. Annals of Internal Medicine, 133, 455-463.
https://doi.org/10.7326/0003-4819-133-6-200009190-00014

[38]   Ellenberg, S.S. and Temple, R. (2000) Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 2: Practical Issues and Specific Cases. Annals of Internal Medicine, 133, 464-470.
https://doi.org/10.7326/0003-4819-133-6-200009190-00015

[39]   Simon, R. (2000) Are Placebo-Controlled Clinical Trials Ethical or Needed When Alternative Treatment Exists? Annals of Internal Medicine, 133, 474-475.
https://doi.org/10.7326/0003-4819-133-6-200009190-00017

[40]   Emanuel, E.J. and Miller, P.G. (2001) The Ethics of Placebo-Controlled Trials—A Middle Ground. New England Journal of Medicine, 345, 915-919.
https://doi.org/10.1056/NEJM200109203451211

[41]   Millum, J. and Grady, C. (2013) The Ethics of Placebo-Controlled Trials: Methodological Justifications. Contemporary Clinical Trials, 36, 510-514.
https://doi.org/10.1016/j.cct.2013.09.003

[42]   Curkovic, M., Zivkovic, M., Radic, K., Maja, et al. (2015) Ethical Overview of Placebo Control in Psychiatric Research—Concepts and Challenges. Psychiatria Danubina, 27, 118-125.

[43]   Levy, M. (2015) The Ethics of Placebo-Controlled Clinical Trials in NMO—A Balance of Risks. Multiple Sclerosis and Related Disorders, 4, 512-514.
https://doi.org/10.1016/j.msard.2015.07.016

[44]   Cheah, P.Y., Steinkamp, N. and von Seidlein, L. (2018) The Ethics of Using Placebo in Randomised Controlled Trials: A Case Study of a Plasmodium Vivaxantirelapse Trial. BMC Medical Ethics, 19, 19.
https://doi.org/10.1186/s12910-018-0259-4

[45]   Skierka, A.S. and Michels, K.B. (2018) Ethical Principles and Placebo-Controlled Trials—Interpretation and Implementation of the Declaration of Helsinki’s Placebo Paragraph in Medical Research. BMC Medical Ethics, 19, 24.
https://doi.org/10.1186/s12910-018-0262-9

[46]   Heckerling, P.S. (2005) The Ethics of Single Blind Trials. Ethics & Human Research, 27, 12-16.
https://doi.org/10.2307/3563956

[47]   Appelbaum, P.S., Roth, L.H. and Lidz, C. (1982) The Therapeutic Misconception: Informed Consent in Psychiatric Research. Journal of Law and Psychiatry, 5, 319-329.
https://doi.org/10.1016/0160-2527(82)90026-7

[48]   Spielmans, G.I. and Parry, P.I. (2010) From Evidence-Based Medicine to Marketing-Based Medicine: Evidence from Internal Industry Documents. Journal of Bioethical Inquiry, 7, 13-29.
https://doi.org/10.1007/s11673-010-9208-8

[49]   Greenhalgh, T., Howick, J. and Maskrey, N. (2014) Evidence Based Medicine: A Movement in Crisis? BMJ, 348, g3725.
https://doi.org/10.1136/bmj.g3725

[50]   Every-Palmer, S. and Howick, J. (2014) How Evidence-Based Medicine Is Failing Due to Biased Trials and Selective Publication. Journal of Evaluation Clinical Practice, 20, 908-914.
https://doi.org/10.1111/jep.12147

[51]   Fava, G.A. (2017) Evidence-Based Medicine Was Bound to Fail: A Report to Alvan Feinstein. Journal of Clinical Epidemiology, 84, 3-7.
https://doi.org/10.1016/j.jclinepi.2017.01.012

[52]   Japanese Law Translation (2009) Industrial Safety and Health Act.
http://www.japaneselawtranslation.go.jp/law/detail/?id=1926&vm=&re

[53]   Nawata, K., Matsumoto, A., Kajihara, K., et al. (2017) Evaluation of the Distribution of and Factors Affecting Blood Pressure Using Medical Checkup Data in Japan. Health, 9, 124-137.
https://doi.org/10.4236/health.2017.91009

[54]   Heckman, J. (1979) Sample Selection Bias as a Specification Error. Econometrica, 47, 153-161.
https://doi.org/10.2307/1912352

[55]   Nawata, K. and Kimura, M. (2017) Reliability of Blood Pressure Measurements: An Analysis of the White Coat Effect and Its Fluctuations. Health, 9, 506-519.
https://doi.org/10.4236/health.2017.93036

[56]   White, H. (1980) A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity. Econometrica, 48, 817-838.
https://doi.org/10.2307/1912934

[57]   Amemiya, T. (1985) Advanced Econometrics. Harvard University Press, Cambridge.

[58]   Nawata, K. (1993) A Note on Estimation of Models with Sample Selection Biases. Economic Letters, 42, 15-24.
https://doi.org/10.1016/0165-1765(93)90167-B

[59]   Nawata, K. (1994) Estimation of Sample Selection Bias Models by the Maximum Likelihood Estimator and Heckman’s Two-Step Estimator. Economic Letters, 45, 33-40.
https://doi.org/10.1016/0165-1765(94)90053-1

 
 
Top